79
Petruzzi M, Lauritano D, De Benedittis M, Serpico R.Systemic capsaicin for burning
mouth syndrome:short-term results of a pilot study. J Oral Pathol Med 2004; 33: 111-
4.
Puri V, Cui L, Liverman CS, Roby KF, Klein RM, Welch KM, et al. Ovarian steroids
regulate neuropeptides in the trigeminal ganglion. Neuropeptides 2005; 39:409-17.
Santoro V, Caputo G, Peluso F. Clinical and Therapeutic experience in twenty eight
patients with burning mouth syndrome. Minerva Stomatol 2005; 54:489-96.
Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A. Benzydamine
hydrocloride oral rinse in management of Burning Mouth Syndrome. Oral Sur Oral
Med Oral Pathol 1999; 88:683-6.
Scala A, Checchi L, Montevecchi M. Update on burning mouth syndrome: overview
and patient management.Crit Rev Oral Biol Med 2003;14:275–91.
Serra MPM, Liorca CS, Donat FJS. Pharmacological treatment of burning mouth
syndrome: a review and update. Med Oral Patol OralCir Bucal 2007;12:299-304.
Ship JA, Grushka M, Lipton JA, Mott AE, Sessle BJ, Dionne RA. Burning Mouth
Syndrome: an update. J Am Dent Assoc 1995;126:842-53.
Silva J, Silva C, Diniz P, Cruz . Instilação intra-vesical dos agonistas do TRPV1:
aplicação terapêutica. Acta Urológica 2006;23:21-30.
Silveira DX, Jorge MR. Propriedades psicométricas da escala de rastreamento
populacional para depressão CES-D em populações clínica e não-clínica de
adolescentes e adultos jovens (1998) disponível em URL
http://www.hcnet.usp.br/ipq/revista/r255/depre255c. [2008jun21].
Spielberger CD, Gorsuch,R.L, Lushene R.E. Manual for the State-Trait Anxiety
Inventory.Consulting Psychologist Press Palo Alto; 1970.
Sreebny LM. Saliva in health and disease: an appraisal and update. Int Den J 2000;
50: 140-61.
Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms.
Pharmacological Reviews 1999;51:160-202.